Unique ID issued by UMIN | UMIN000020503 |
---|---|
Receipt number | R000023671 |
Scientific Title | Effect of supplement containing N-acetyl glucosamine, proteoglycan and lutein, on knee joint symptoms. - a randomized, double blind, placebo-controlled study - |
Date of disclosure of the study information | 2016/07/01 |
Last modified on | 2016/08/19 10:40:49 |
Effect of supplement containing N-acetyl glucosamine, proteoglycan and lutein, on knee joint symptoms. - a randomized, double blind, placebo-controlled study -
Effect of supplement containing N-acetyl glucosamine, proteoglycan and lutein, on knee joint symptoms.
Effect of supplement containing N-acetyl glucosamine, proteoglycan and lutein, on knee joint symptoms. - a randomized, double blind, placebo-controlled study -
Effect of supplement containing N-acetyl glucosamine, proteoglycan and lutein, on knee joint symptoms.
Japan |
Healthy volunteer
Adult |
Others
NO
This study aims to evaluate the effect of ingestion of supplement containing N-acetyl glucosamine, proteoglycan and lutein, on knee joint subjective symptoms.
Efficacy
JKOM and Knee Society Score(ver 2011)
knee joint subjective symptoms(VAS)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Ingestion of supplement containing N-acetyl glucosamine, proteoglycan complex and lutein for 12 weeks
Ingestion of placebo without N-acetyl glucosamine, proteoglycan complex and lutein for 12 weeks
30 | years-old | <= |
64 | years-old | >= |
Male and Female
1) Subject, aged from 30 to 65 years Males and females with uncomfortable feeling of knee
2) Subject, be diagnosed KLgrade 0 or 1
3) Subject, upon briefing of the content of the present study, fully understanding and agreeing to its objective; and being able to personally sign a written informed consent
1)Subjects having a medical history of rheumatism
2)Subjects who have leg pain or numbness
3)Subjects who have injury of semi-lunar disc or the other knee joint disease
4)Subjects receiving treatment for osteoarthritis
5)Subject receiving treatment for serious liver, renal, cardio-vascular, respiratory, endocrine, or metabolic disorders
6)Subject presenting known allergy or history of hypersensitivity to gelatin, crab and salmon
7)For female subject: pregnancy or breast feeding, or possibility of pregnancy, or intention to be pregnant during the study
8)Subject having blood sample of 200 ml or more taken (e.g., donated blood) within 1 month, or 400 ml or more within 3 months prior to the start of the present study
9)Subject who took part in another clinical trial within 3 months prior to the start of the present study or who is currently taking part in another clinical trial
10)Subject deemed unsuitable by the investigator
80
1st name | |
Middle name | |
Last name | Osami Kajimoto |
Osaka City University Graduate School of Medicine
Department of Medical Science on Fatigue
1-4-3, Asahi-machi, Abeno-ku, Osaka, Osaka
06-6645-6171
kajimoto@med.osaka-cu.ac.jp
1st name | |
Middle name | |
Last name | Tomohiro Sugino |
Soiken Inc.
President & CEO
Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka, Osaka
06-6871-8888
sugino@soiken.com
Soiken Inc.
FANCL Corporation
Profit organization
Japan
NO
医療法人弘正会ふくだ内科クリニック(大阪府)
2016 | Year | 07 | Month | 01 | Day |
Unpublished
Completed
2015 | Year | 12 | Month | 19 | Day |
2016 | Year | 01 | Month | 09 | Day |
2016 | Year | 01 | Month | 08 | Day |
2016 | Year | 08 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023671